Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ph-positive leukemia: a transgenic mouse model

J Groffen1, J W Voncken, V Kaartinen

  • 1Department of Pathology, Children's Hospital of Los Angeles, CA 90027.

Leukemia & Lymphoma
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving on-call efficiency: impact of the orthopaedic grab-bag in major trauma centres and trauma units.

Annals of the Royal College of Surgeons of England·2026
Same author

How can we use distance education to teach medicine in conflict-affected countries?

Medicine, conflict, and survival·2024
Same author

The World Rugby and International Rugby Players Contact Load Guidelines: From conception to implementation and the future.

South African journal of sports medicine·2024
Same author

Scintillation light detection in the 6-m drift-length ProtoDUNE Dual Phase liquid argon TPC.

The European physical journal. C, Particles and fields·2022
Same author

Effect of different durations of using a standing frame on the rate of hip migration in children with moderate to severe cerebral palsy: a feasibility study for a randomised controlled trial.

Physiotherapy·2022
Same author

Prospects for beyond the Standard Model physics searches at the Deep Underground Neutrino Experiment: DUNE Collaboration.

The European physical journal. C, Particles and fields·2021
Same journal

Glofitamab for the treatment of relapsed/refractory hairy cell leukemia: a case report.

Leukemia & lymphoma·2026
Same journal

Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia.

Leukemia & lymphoma·2026
Same journal

Leukemia mortality analysis in the pediatric population in São Paulo state, Brazil, 2000-2019.

Leukemia & lymphoma·2026
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
See all related articles

A BCR/ABL (P190) transgenic mouse model rapidly develops leukemia, revealing the BCR/ABL gene

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The BCR/ABL chimeric gene is a key indicator in specific human leukemias.
  • Understanding its oncogenic mechanisms is crucial for developing effective treatments.
  • A transgenic mouse model offers a platform for studying BCR/ABL-induced leukemia.

Purpose of the Study:

  • To establish a BCR/ABL (P190) transgenic mouse model for human leukemia.
  • To investigate the role of BCR/ABL in leukemogenesis and cell cycle regulation.
  • To determine the tissue-specific oncogenicity of BCR/ABL.

Main Methods:

  • Generation of a BCR/ABL (P190) transgenic mouse line.
  • Monitoring of leukemia development and survival rates in the mouse line.
  • Karyotypic analysis of leukemia cells at different stages.

Related Experiment Videos

  • Assessment of BCR/ABL expression in various tissues.

    • Main Results:

    • Over 95% of BCR/ABL (P190) transgenic mice developed leukemia/lymphoma within 35-200 days.
    • Early stages of leukemia lacked detectable genetic alterations, with aneuploidy emerging in advanced stages.
    • BCR/ABL expression was observed in non-hematopoietic tissues but did not lead to solid tumors.
    • BCR/ABL appears to destabilize cell cycle regulation, primarily impacting the hematopoietic lineage.

    Conclusions:

    • The BCR/ABL (P190) transgenic mouse model effectively recapitulates human leukemia.
    • BCR/ABL plays a critical role in initiating leukemia and is associated with cell cycle dysregulation.
    • The oncogenic activity of BCR/ABL is predominantly confined to hematopoietic cells.